Engineered immune cells for B-cell leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a new treatment using immune cells from donated umbilical cord blood to fight a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). The cells are engineered to target and kill cancer cells, which may help even if other treatments haven't worked.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have a confirmed diagnosis of B-cell acute lymphoblastic leukemia (a type of blood cancer).
- Your leukemia cells must test positive for CD19 or CD20 markers (proteins on the surface of cancer cells).
- You should be generally well enough to be up and about (not bedridden), and your kidney and liver function should be within acceptable limits.
- You must not have active leukemia in the brain or spinal fluid, and you must not have certain severe heart, lung, or brain conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new way to treat B-cell acute lymphoblastic leukemia (B-ALL). The treatment takes your own immune cells, changes them to fight cancer, and then gives them back to you. The goal is to kill leukemia cells and help you go into remission.
This trial tests a new type of personalized cell therapy using your own immune cells (called CAR-T cells) that are designed to find and attack leukemia cells that have certain markers (CD19 and CD22). It is for people whose leukemia has returned or not responded to standard treatments.
This trial tests whether CAR-T cells made from a healthy donor can help treat B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. It's for adults who cannot use their own cells for CAR-T therapy.
This trial tests a combination of two different engineered immune cell therapies to treat B-ALL (a leukemia). It’s designed for young people whose disease has come back, is hard to treat, or didn’t respond well to similar cell therapies.
This trial tests a new type of CAR-T cell therapy for people with B-cell acute lymphoblastic leukemia that has returned or not responded to standard treatment. The CAR-T cells are made from a donor and modified to target the CD19 protein on leukemia cells.
This trial tests a new type of immune cell therapy (CAR-T) that uses donor cells to target and kill leukemia cells. It is for adults with B-cell acute lymphoblastic leukemia that has not responded to at least two prior treatments.
Hear when a new B-Cell Acute Lymphoblastic Leukemia, Adult trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.